表紙
市場調査レポート

Bolder Biotechnology, Inc.の製品パイプライン分析

Bolder Biotechnology, Inc. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 253705
出版日 ページ情報 英文 29 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
Bolder Biotechnology, Inc.の製品パイプライン分析 Bolder Biotechnology, Inc. - Product Pipeline Review - 2016
出版日: 2016年02月24日 ページ情報: 英文 29 Pages
概要

Bolder Biotechnology, Inc.は米国に本社をおく製薬企業で、成長ホルモン、βインターフェロン、ガンマインターフェロン、エリスロポエチン、長時間作用型EPO、αインターフェロンなど特許を持つヒト用タンパク質性医薬品を提供しています。同社の製品は血液疾患、内分泌疾患、感染症、がんなどの疾患に対する効果が期待されています。

当レポートでは、Bolder Biotechnology, Inc. における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Bolder Biotechnology, Inc. の基本情報

  • Bolder Biotechnology, Inc. の概要
  • 主要情報
  • 企業情報

Bolder Biotechnology, Inc. :R&Dの概要

  • 主な治療範囲

Bolder Biotechnology, Inc. :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • 併用療法モダリティ
  • パートナー製品
  • アウトライセンス製品

Bolder Biotechnology, Inc. :パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬段階にある製品/併用療法モダリティ

Bolder Biotechnology, Inc.:薬剤プロファイル

  • BBT-007
  • BBT-009
  • BBT-015
  • BBT-018
  • BBT-021
  • BBT-030
  • BBT-031
  • BBT-032
  • BBT-045
  • BBT-046
  • BBT-012

Bolder Biotechnology, Inc. :パイプライン分析

  • 標的別
  • 分子タイプ別
  • 作用機序別

Bolder Biotechnology, Inc. :最新のパイプライン情報

Bolder Biotechnology, Inc. :開発休止中のプロジェクト

Bolder Biotechnology, Inc. :本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07954CDB

Summary

Global Markets Direct's, 'Bolder Biotechnology, Inc. - Product Pipeline Review - 2016', provides an overview of the Bolder Biotechnology, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Bolder Biotechnology, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Bolder Biotechnology, Inc.
  • The report provides overview of Bolder Biotechnology, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Bolder Biotechnology, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Bolder Biotechnology, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Bolder Biotechnology, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Bolder Biotechnology, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bolder Biotechnology, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Bolder Biotechnology, Inc. Snapshot
    • Bolder Biotechnology, Inc. Overview
    • Key Information
    • Key Facts
  • Bolder Biotechnology, Inc. - Research and Development Overview
  • Key Therapeutic Areas
  • Bolder Biotechnology, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Bolder Biotechnology, Inc. - Pipeline Products Glance
  • Bolder Biotechnology, Inc. - Early Stage Pipeline Products
  • Preclinical Products/Combination Treatment Modalities
  • Discovery Products/Combination Treatment Modalities
  • Bolder Biotechnology, Inc. - Drug Profiles
    • BBT-007
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BBT-009
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BBT-015
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BBT-018
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BBT-021
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BBT-031
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BBT-032
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BBT-046
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BBT-059
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BBT-012
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Bolder Biotechnology, Inc. - Pipeline Analysis
    • Bolder Biotechnology, Inc. - Pipeline Products by Target
    • Bolder Biotechnology, Inc. - Pipeline Products by Molecule Type
    • Bolder Biotechnology, Inc. - Pipeline Products by Mechanism of Action
  • Bolder Biotechnology, Inc. - Dormant Projects
  • Bolder Biotechnology, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Bolder Biotechnology, Inc., Key Information
  • Bolder Biotechnology, Inc., Key Facts
  • Bolder Biotechnology, Inc. - Pipeline by Indication, 2016
  • Bolder Biotechnology, Inc. - Pipeline by Stage of Development, 2016
  • Bolder Biotechnology, Inc. - Monotherapy Products in Pipeline, 2016
  • Bolder Biotechnology, Inc. - Preclinical, 2016
  • Bolder Biotechnology, Inc. - Discovery, 2016
  • Bolder Biotechnology, Inc. - Pipeline by Target, 2016
  • Bolder Biotechnology, Inc. - Pipeline by Molecule Type, 2016
  • Bolder Biotechnology, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Bolder Biotechnology, Inc. - Dormant Developmental Projects,2016

List of Figures

  • Bolder Biotechnology, Inc. - Pipeline by Top 10 Indication, 2016
  • Bolder Biotechnology, Inc. - Pipeline by Stage of Development, 2016
  • Bolder Biotechnology, Inc. - Monotherapy Products in Pipeline, 2016
  • Bolder Biotechnology, Inc. - Pipeline by Target, 2016
  • Bolder Biotechnology, Inc. - Pipeline by Molecule Type, 2016
  • Bolder Biotechnology, Inc. - Pipeline Products by Mechanism of Action, 2016
Back to Top